---
annotation-target: pnas202020382.pdf
---


>%%
>```annotation-json
>{"created":"2022-08-08T05:36:28.113Z","updated":"2022-08-08T05:36:28.113Z","document":{"title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","link":[{"href":"urn:x-pdf:63108d22d3413f5411b59f1df7dd226f"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf"}],"documentFingerprint":"63108d22d3413f5411b59f1df7dd226f"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","selector":[{"type":"TextPositionSelector","start":5911,"end":6052},{"type":"TextQuoteSelector","exact":"The APL2012 trial is currently the largest randomized, multi-center clinical study of APL based on ATRA-ATO treatment withrisk stratification","prefix":") was initially usedSignificance","suffix":". We enrolled 855 newly diagnose"}]}]}
>```
>%%
>*%%PREFIX%%) was initially usedSignificance%%HIGHLIGHT%% ==The APL2012 trial is currently the largest randomized, multi-center clinical study of APL based on ATRA-ATO treatment withrisk stratification== %%POSTFIX%%. We enrolled 855 newly diagnose*
>%%LINK%%[[#^nhmnt9jy28|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^nhmnt9jy28


>%%
>```annotation-json
>{"created":"2022-08-08T05:37:11.839Z","updated":"2022-08-08T05:37:11.839Z","document":{"title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","link":[{"href":"urn:x-pdf:63108d22d3413f5411b59f1df7dd226f"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf"}],"documentFingerprint":"63108d22d3413f5411b59f1df7dd226f"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","selector":[{"type":"TextPositionSelector","start":6158,"end":6554},{"type":"TextQuoteSelector","exact":"All patients received ATRA-ATO–based protocols for remissioninduction. At the consolidation phase, the key part of the trial,ATO was used to replace or reduce chemotherapy in a risk-stratified way. Patients were then treated with ATRA-ATO asmaintenance. The results indicated not only the noninferiority ofATO compared to intensive chemotherapy in survival but also anadvantage in adverse effects","prefix":"mber 2017 for careful follow-up.","suffix":". The trial provides support for"}]}]}
>```
>%%
>*%%PREFIX%%mber 2017 for careful follow-up.%%HIGHLIGHT%% ==All patients received ATRA-ATO–based protocols for remissioninduction. At the consolidation phase, the key part of the trial,ATO was used to replace or reduce chemotherapy in a risk-stratified way. Patients were then treated with ATRA-ATO asmaintenance. The results indicated not only the noninferiority ofATO compared to intensive chemotherapy in survival but also anadvantage in adverse effects== %%POSTFIX%%. The trial provides support for*
>%%LINK%%[[#^7f5ba7rra6i|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^7f5ba7rra6i


>%%
>```annotation-json
>{"created":"2022-08-08T05:37:33.681Z","text":"蒽环类药物","updated":"2022-08-08T05:37:33.681Z","document":{"title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","link":[{"href":"urn:x-pdf:63108d22d3413f5411b59f1df7dd226f"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf"}],"documentFingerprint":"63108d22d3413f5411b59f1df7dd226f"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","selector":[{"type":"TextPositionSelector","start":5605,"end":5617},{"type":"TextQuoteSelector","exact":"anthracyclin","prefix":"tinoic acid (ATRA) combinedwith ","suffix":"e-based chemotherapy has remarka"}]}]}
>```
>%%
>*%%PREFIX%%tinoic acid (ATRA) combinedwith%%HIGHLIGHT%% ==anthracyclin== %%POSTFIX%%e-based chemotherapy has remarka*
>%%LINK%%[[#^m5fr7atq0b|show annotation]]
>%%COMMENT%%
>蒽环类药物
>%%TAGS%%
>
^m5fr7atq0b


>%%
>```annotation-json
>{"created":"2022-08-08T05:38:17.617Z","text":" 砒霜,三氧化二砷","updated":"2022-08-08T05:38:17.617Z","document":{"title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","link":[{"href":"urn:x-pdf:63108d22d3413f5411b59f1df7dd226f"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf"}],"documentFingerprint":"63108d22d3413f5411b59f1df7dd226f"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","selector":[{"type":"TextPositionSelector","start":5812,"end":5895},{"type":"TextQuoteSelector","exact":" For patients relapsed fromATRA-chemotherapy, arsenic trioxide (ATO) was initially ","prefix":"to 80% long-term survival (1–6).","suffix":"usedSignificanceThe APL2012 tria"}]}]}
>```
>%%
>*%%PREFIX%%to 80% long-term survival (1–6).%%HIGHLIGHT%% ==For patients relapsed fromATRA-chemotherapy, arsenic trioxide (ATO) was initially== %%POSTFIX%%usedSignificanceThe APL2012 tria*
>%%LINK%%[[#^cmh66u3ilqu|show annotation]]
>%%COMMENT%%
> 砒霜,三氧化二砷
>%%TAGS%%
>
^cmh66u3ilqu


>%%
>```annotation-json
>{"created":"2022-08-08T05:39:29.430Z","text":"吉妥珠单抗臭氧组胺素\n降档细胞毒性方案","updated":"2022-08-08T05:39:29.430Z","document":{"title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","link":[{"href":"urn:x-pdf:63108d22d3413f5411b59f1df7dd226f"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf"}],"documentFingerprint":"63108d22d3413f5411b59f1df7dd226f"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","selector":[{"type":"TextPositionSelector","start":8280,"end":8554},{"type":"TextQuoteSelector","exact":" Meanwhile, an exploratory study onATRA-ATO with or without gemtuzumab ozogamicin (GO, thecytotoxic agent calicheamicin linked an anti-CD33 monoclonalantibody) by the MD Anderson Cancer Center suggested that adeescalating cytotoxic regimen might be feasible for APL patients","prefix":"rnationalworking groups (14–18).","suffix":"(14, 19).A large body of evidenc"}]}]}
>```
>%%
>*%%PREFIX%%rnationalworking groups (14–18).%%HIGHLIGHT%% ==Meanwhile, an exploratory study onATRA-ATO with or without gemtuzumab ozogamicin (GO, thecytotoxic agent calicheamicin linked an anti-CD33 monoclonalantibody) by the MD Anderson Cancer Center suggested that adeescalating cytotoxic regimen might be feasible for APL patients== %%POSTFIX%%(14, 19).A large body of evidenc*
>%%LINK%%[[#^d0maczn5tem|show annotation]]
>%%COMMENT%%
>吉妥珠单抗臭氧组胺素
>降档细胞毒性方案
>%%TAGS%%
>
^d0maczn5tem


>%%
>```annotation-json
>{"created":"2022-08-08T05:40:57.461Z","updated":"2022-08-08T05:40:57.461Z","document":{"title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","link":[{"href":"urn:x-pdf:63108d22d3413f5411b59f1df7dd226f"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf"}],"documentFingerprint":"63108d22d3413f5411b59f1df7dd226f"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","selector":[{"type":"TextPositionSelector","start":8563,"end":8782},{"type":"TextQuoteSelector","exact":"A large body of evidence has been obtained to show that bothATRA and ATO target the APL-specific PML-RARA onco-protein and the two agents may exert a synergistic effect in achievinga curative clinical effect in most APL","prefix":"asible for APL patients(14, 19).","suffix":" (2, 9). However, in our previou"}]}]}
>```
>%%
>*%%PREFIX%%asible for APL patients(14, 19).%%HIGHLIGHT%% ==A large body of evidence has been obtained to show that bothATRA and ATO target the APL-specific PML-RARA onco-protein and the two agents may exert a synergistic effect in achievinga curative clinical effect in most APL== %%POSTFIX%%(2, 9). However, in our previou*
>%%LINK%%[[#^lzje7jbirvs|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^lzje7jbirvs


>%%
>```annotation-json
>{"created":"2022-08-08T05:41:42.732Z","updated":"2022-08-08T05:41:42.732Z","document":{"title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","link":[{"href":"urn:x-pdf:63108d22d3413f5411b59f1df7dd226f"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf"}],"documentFingerprint":"63108d22d3413f5411b59f1df7dd226f"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","selector":[{"type":"TextPositionSelector","start":9113,"end":9303},{"type":"TextQuoteSelector","exact":" overtreatment for low- risk (a white blood cell [WBC] count ≤10 ×109/L and a platelet count >40 ×109/L) to intermediate-risk(a WBC count ≤10 ×109/L and a platelet count ≤40 ×109/L)patients ","prefix":"introduced, leading to proba-ble","suffix":"(20). These issues warranted fur"}]}]}
>```
>%%
>*%%PREFIX%%introduced, leading to proba-ble%%HIGHLIGHT%% ==overtreatment for low- risk (a white blood cell [WBC] count ≤10 ×109/L and a platelet count >40 ×109/L) to intermediate-risk(a WBC count ≤10 ×109/L and a platelet count ≤40 ×109/L)patients== %%POSTFIX%%(20). These issues warranted fur*
>%%LINK%%[[#^7yvb1kxkkey|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^7yvb1kxkkey


>%%
>```annotation-json
>{"created":"2022-08-08T05:42:07.070Z","updated":"2022-08-08T05:42:07.070Z","document":{"title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","link":[{"href":"urn:x-pdf:63108d22d3413f5411b59f1df7dd226f"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf"}],"documentFingerprint":"63108d22d3413f5411b59f1df7dd226f"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","selector":[{"type":"TextPositionSelector","start":10493,"end":10510},{"type":"TextQuoteSelector","exact":"Induction Therapy","prefix":"atients are provided in Table 1.","suffix":". Among the 855 patients, 8 were"}]}]}
>```
>%%
>*%%PREFIX%%atients are provided in Table 1.%%HIGHLIGHT%% ==Induction Therapy== %%POSTFIX%%. Among the 855 patients, 8 were*
>%%LINK%%[[#^3ezqbujygr5|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^3ezqbujygr5


>%%
>```annotation-json
>{"created":"2022-08-08T05:42:17.566Z","updated":"2022-08-08T05:42:17.566Z","document":{"title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","link":[{"href":"urn:x-pdf:63108d22d3413f5411b59f1df7dd226f"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf"}],"documentFingerprint":"63108d22d3413f5411b59f1df7dd226f"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","selector":[{"type":"TextPositionSelector","start":12155,"end":12176},{"type":"TextQuoteSelector","exact":"Consolidation Therapy","prefix":"ation therapy.Randomization and ","suffix":". Of the 813 patients whoachieve"}]}]}
>```
>%%
>*%%PREFIX%%ation therapy.Randomization and%%HIGHLIGHT%% ==Consolidation Therapy== %%POSTFIX%%. Of the 813 patients whoachieve*
>%%LINK%%[[#^41yrlxo33yj|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^41yrlxo33yj


>%%
>```annotation-json
>{"created":"2022-08-08T05:42:32.687Z","updated":"2022-08-08T05:42:32.687Z","document":{"title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","link":[{"href":"urn:x-pdf:63108d22d3413f5411b59f1df7dd226f"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf"}],"documentFingerprint":"63108d22d3413f5411b59f1df7dd226f"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","selector":[{"type":"TextPositionSelector","start":13622,"end":13641},{"type":"TextQuoteSelector","exact":"Maintenance Therapy","prefix":"ce therapy and the ITT analysis.","suffix":". At the end of consolidation th"}]}]}
>```
>%%
>*%%PREFIX%%ce therapy and the ITT analysis.%%HIGHLIGHT%% ==Maintenance Therapy== %%POSTFIX%%. At the end of consolidation th*
>%%LINK%%[[#^mwua824o6gf|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^mwua824o6gf


>%%
>```annotation-json
>{"created":"2022-08-08T05:43:00.706Z","updated":"2022-08-08T05:43:00.706Z","document":{"title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","link":[{"href":"urn:x-pdf:63108d22d3413f5411b59f1df7dd226f"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf"}],"documentFingerprint":"63108d22d3413f5411b59f1df7dd226f"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","selector":[{"type":"TextPositionSelector","start":17196,"end":17215},{"type":"TextQuoteSelector","exact":"Primary End Point. ","prefix":"listed in SI Appendix, Table S1.","suffix":"The last follow-up was performed"}]}]}
>```
>%%
>*%%PREFIX%%listed in SI Appendix, Table S1.%%HIGHLIGHT%% ==Primary End Point.== %%POSTFIX%%The last follow-up was performed*
>%%LINK%%[[#^g23xzy5m49v|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^g23xzy5m49v


>%%
>```annotation-json
>{"created":"2022-08-08T05:44:03.588Z","updated":"2022-08-08T05:44:03.588Z","document":{"title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","link":[{"href":"urn:x-pdf:63108d22d3413f5411b59f1df7dd226f"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf"}],"documentFingerprint":"63108d22d3413f5411b59f1df7dd226f"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","selector":[{"type":"TextPositionSelector","start":26231,"end":26375},{"type":"TextQuoteSelector","exact":"thus the chemotherapy-free and cytarabine-free strategiescould be used for patients in low-/intermediate-risk and high-riskgroups, respectively.","prefix":"terms of long-term survival,and ","suffix":"The extraordinary effect of ATRA"}]}]}
>```
>%%
>*%%PREFIX%%terms of long-term survival,and%%HIGHLIGHT%% ==thus the chemotherapy-free and cytarabine-free strategiescould be used for patients in low-/intermediate-risk and high-riskgroups, respectively.== %%POSTFIX%%The extraordinary effect of ATRA*
>%%LINK%%[[#^5dut5nr2ec6|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^5dut5nr2ec6


>%%
>```annotation-json
>{"created":"2022-08-08T05:45:09.928Z","updated":"2022-08-08T05:45:09.928Z","document":{"title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","link":[{"href":"urn:x-pdf:63108d22d3413f5411b59f1df7dd226f"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf"}],"documentFingerprint":"63108d22d3413f5411b59f1df7dd226f"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","selector":[{"type":"TextPositionSelector","start":27098,"end":27301},{"type":"TextQuoteSelector","exact":"Like the APL0406 trial, patients of both low- and intermediate-risk categories in our study have benefited from the therapeuticeffects of ATO in replacement of anthracyclines in the consoli-dation phase.","prefix":" ATO at the consolidation phase.","suffix":" However, different from the ATR"}]}]}
>```
>%%
>*%%PREFIX%%ATO at the consolidation phase.%%HIGHLIGHT%% ==Like the APL0406 trial, patients of both low- and intermediate-risk categories in our study have benefited from the therapeuticeffects of ATO in replacement of anthracyclines in the consoli-dation phase.== %%POSTFIX%%However, different from the ATR*
>%%LINK%%[[#^5dkjmxnmcme|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^5dkjmxnmcme


>%%
>```annotation-json
>{"created":"2022-08-08T05:46:22.769Z","updated":"2022-08-08T05:46:22.769Z","document":{"title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","link":[{"href":"urn:x-pdf:63108d22d3413f5411b59f1df7dd226f"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf"}],"documentFingerprint":"63108d22d3413f5411b59f1df7dd226f"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","selector":[{"type":"TextPositionSelector","start":27720,"end":27864},{"type":"TextQuoteSelector","exact":" Our study confirmed that chemotherapy-free or “replacing”strategy was feasible among low- and intermediate-risk patientsafter induction therapy","prefix":"py group (77.4%) in APL0406(26).","suffix":".However, high-risk patients sti"}]}]}
>```
>%%
>*%%PREFIX%%py group (77.4%) in APL0406(26).%%HIGHLIGHT%% ==Our study confirmed that chemotherapy-free or “replacing”strategy was feasible among low- and intermediate-risk patientsafter induction therapy== %%POSTFIX%%.However, high-risk patients sti*
>%%LINK%%[[#^emkksazolpl|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^emkksazolpl


>%%
>```annotation-json
>{"created":"2022-08-08T05:46:44.037Z","updated":"2022-08-08T05:46:44.037Z","document":{"title":"Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)","link":[{"href":"urn:x-pdf:63108d22d3413f5411b59f1df7dd226f"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf"}],"documentFingerprint":"63108d22d3413f5411b59f1df7dd226f"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/pnas202020382.pdf","selector":[{"type":"TextPositionSelector","start":27865,"end":27998},{"type":"TextQuoteSelector","exact":"However, high-risk patients still bear unsatisfactory prognosiswith both early death and relapse representing the treatmentbottleneck","prefix":"patientsafter induction therapy.","suffix":". Even though researchers from t"}]}]}
>```
>%%
>*%%PREFIX%%patientsafter induction therapy.%%HIGHLIGHT%% ==However, high-risk patients still bear unsatisfactory prognosiswith both early death and relapse representing the treatmentbottleneck== %%POSTFIX%%. Even though researchers from t*
>%%LINK%%[[#^o9okv3qfh7|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^o9okv3qfh7
